Severe COVID-19 Pneumonia and Genetic Susceptibility: A Case Report and Literature Review

Badr A. Alsayed 1 , Rashid Mir 2

1. Internal Medicine, University of Tabuk, Tabuk, SAU 2. Molecular Oncology, Genetics and Translational Medicine, Faculty of Applied Medical Sciences, Tabuk, SAU

Abstract

 Genetic susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) morbidity and mortality continues to evolve. This report presents a case of an apparently healthy male adult who developed severe coronavirus disease 2019 (COVID-19) and a study on relevant genetic mutations, namely, angiotensin-converting enzyme 2 (ACE2-rs4646994 I/D) gene, glutathione S-transferase (GST) M1 and T1 gene, and miR-423 rs6505162 C>A gene polymorphism. Results showed that the ACE-DD genotype of ACE2, (GSTM1+/+) (GSTT1−/−) genotype of GST gene, and CA genotype (heterozygosity) of miR-423 rs6505162 genes, which were found in the patient, could be independent risk factors of severe COVID-19, even without comorbidities.

Introduction

Older patients and patients with comorbidities carry a higher risk for severe coronavirus disease 2019 (COVID-19) morbidity and mortality [1]. However, younger age groups, who generally have no chronic illnesses, may also suffer significantly from severe COVID-19 and its complications. COVID-19 outcomes vary between countries and different ethnicities; hence, researchers are encouraged to conduct genetic studies to explain this observation. Angiotensin-converting enzyme 2 (ACE2-rs4646994 I/D) gene, glutathione S-transferase (GST) M1 and T1 gene, and miR-423 rs6505162 C>A gene polymorphism may play a role in the host’s immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1-3]. Regarding disease management, portable chest x-ray (CXR) may be considered in the initial evaluation to minimize cross-infection risk and to avoid disrupting radiological services availability; however, it is an insufficient diagnostic tool for complicated COVID-19 cases [4]. The treatment dose of anticoagulation has been recommended for severe COVID-19, but it has risk factors that should be addressed.

Case Presentation

A 29-year-old male of Asian descent presented to our ER on April 22, 2021, complaining of fever, cough, and progressive dyspnea for the past five days. He worked as a blacksmith, did not smoke, and had no known chronic illnesses. Physical examination revealed a fair physique (BMI, 26 kg/m2), mild respiratory distress (22 breaths/minute), fever (38.5°C), and low normal oxygen saturation (O2Sat) (92% on ambient air); heart rate and blood pressure remained within the normal range (95 beats/minute, 101/56 mmHg). In chest examination, equal bilateral air entry with diffuse bronchial breathing and inspiratory crackles was found. Other systemic examinations were unremarkable. A reverse-transcriptase polymerase chain reaction (RT-PCR) assay from a nasopharyngeal swab detected SARS-CoV-2 RNA. Laboratory results were as follows: total white blood cell count, 6.5 × 10⁹/L; hemoglobin, 15.8 g/dL; platelet, from 154 × 10⁹/L to 103 × 10⁹/L; D-dimer, 1650 ng/mL, creatinine kinase (CK), 2420 IU/L; creatinine kinase-myocardial band (CK-MB), 43 IU/L; lactate dehydrogenase, 994 U/L; total bilirubin, 107 μmol/L (mainly indirect). Arterial blood gas results were the following: pH, 7.347; partial pressure of arterial oxygen (PaO₂), 66 mm Hg; partial pressure of carbon dioxide, 47.5 mm Hg; and bicarbonate (HCO₃), 22 mEq/L. Additionally, electrocardiography detected sinus rhythm. However, CXR showed bilateral opacities involving more than one lobe in each lung, with suspicious shadows of cavitary lesions (Figure 1).
FIGURE 1: Chest x-ray shows bilateral parahilar and peripheral-based opacities, cavity-like radiolucent lesions (black arrows).

Thus, he was found to have a severe bilateral COVID-19 pneumonia with impending cytokine storm. He then started taking an anticoagulant as a treatment dose (subcutaneous enoxaparin, 40 mg twice a day). Unfortunately, two days later, he became more dyspneic (31 breaths/minute), could not maintain O₂Sat, and needed a non-rebreathing mask with 100% oxygen. He started manifesting significant hemoptysis; hence, anticoagulation de-escalated to a prophylactic dose. He was then shifted to the ICU. Computed tomography pulmonary angiogram (CTPA), which can rule out acute pulmonary embolism, could not be performed because of technical reasons and infection control protocols. A workup for cavitary lung lesions was conducted, and the results were as follows: sputum samples negative for acid-fast bacilli, no growth in sputum culture, normal renal functions, and unremarkable autoimmune panel examination. Over five days, no massive hemoptysis occurred. Although he lost approximately 1.5 g of hemoglobin, he did not require any blood transfusion. Eventually, hemoptysis stopped. In line with the Saudi Ministry of Health COVID-19 management protocol [5], the patient received antiviral therapy (favipiravir) as loading and maintenance doses in addition to systemic hydrocortisone and prophylactic dose anticoagulation.

Given the occurrence of hemoptysis after a therapeutic dose of anticoagulation followed by clinical stabilization with antiviral therapy, supportive measures, and prophylactic doses of anticoagulants, we deferred CTPA. High-resolution computed tomography (HRCT) of the chest showed a pattern of COVID-19 with overlapping shadows indicating CXR pseudo-cavitation findings (Figure 2). Three months after hospitalization, a follow-up CXR showed a complete resolution of COVID-19 consolidation.
FIGURE 2: Chest HRCT shows bilateral peripheral ground-glass opacification and consolidation

HRCT: high resolution computer tomography

Materials and methodology

Genomic DNA Extraction

A peripheral blood sample (2 ml) was collected in an ethylenediaminetetraacetic acid (EDTA) or Lavender top tube from the patient. The specimen was immediately stored at -30°C until processed. DNA isolation was done using DNeasy® Blood & Tissue Cat. No. 69504 (QIAGEN, Hilden, Germany) using manufacturer’s instructions. Genomic DNA was isolated from the patient as well as eight healthy controls. All samples were subjected to integrity, purity, and quality check by determining the optical density (OD) at 260 nm and 280 nm using NanoDrop™ One spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The OD determined was 1.90 indicating a good quality DNA.

Determination of Insertion-Deletion of Angiotensin-Converting Enzyme 2 (ACE2) Gene

ACE2 insertion-deletion polymorphism (ACE2-rs4646994I/D) was determined by optimizing mutation-specific PCR (MS-PCR). The primers were designed using the Primer3 software as depicted in Table 1. Similar MS-PCR primers were used previously by Mir et al. [6]. Genomic DNA (50 ng) was amplified in a reaction volume of 25 µL, which contained 25 pmol of each of the primers given in Table 1 and 12 µL from Promega® PCR Master Mix (2x) (Cat. No. M7502-US) (Promega Corporation, Madison, Wisconsin, United States) and volume were adjusted to a final volume of 25 µL by adding nuclease-free double-distilled water (ddH2O).
PCR primers of ACE2-rs4646994 I/D gene polymorphism

| Direction | Primer Sequence | PCR Product | Annealing Temperature |
|-----------|----------------|-------------|-----------------------|
| ACE-F     | 5′-CTGGAGACCACTCCCATCTTTCT-3′ | 490 bp (II) | 58 °C                 |
| ACE-R     | 5′-GATGTCGGCGCATGACGAT-3′       | 190 bp (DD) |                       |

**TABLE 1: PCR primers of ACE2-rs4646994 I/D gene polymorphism**

PCR: polymerase chain reaction; ACE2: angiotensin-converting enzyme 2

Finally, we added 2 µL of the patient’s DNA. The thermocycling conditions used were 95°C for eight minutes followed by 45 cycles of 95°C for 35 seconds, annealing temperature at 58°C for 40 seconds, and extension at 72°C for 45 seconds followed by the final extension at 72°C for 10 minutes. The PCR products were electrophoresed on a 2% agarose gel stained with ethidium bromide to visualize three patterns: I/I (490 bp fragment), D/D (190 bp fragment), and I/D (both 490 and 190 bp fragments).

**Multiplex PCR GST M1 and T1 Genotyping**

GST M1 and T1 genotyping were performed by multiplex PCR. The primers were also used previously (Table 2) [7]. Patient and control genomic DNA (50 ng) was amplified in a reaction volume of 25 µL, which was composed of 25 pmol of each of the primers depicted in Table 2. Six primers were used, 12 µL from Promega PCR Master Mix (2x) (Cat. No. M7502-US) was added, and the final volume was adjusted to 25 µL by adding nuclease-free ddH2O. Finally, we added 2 µL of the DNA sample of the patient. Multiplex PCR was performed to detect the GSTT1 and GSTM1 presence in the genomic DNA samples of patients and healthy controls. The cycling conditions comprised a hot start at 95°C for 10 minutes, followed by 35 amplification cycles at 95°C for 35 seconds, 59°C for 40 seconds, and 72°C for 58 seconds followed by one elongation step at 72°C for 10 minutes and storage at 4°C.

**TABLE 2: Glutathione S-transferase (GST) M1 and T1 primers**

PCR: polymerase chain reaction

| Gene   | Primer sequence | Annealing temperature | PCR products |
|--------|-----------------|-----------------------|--------------|
| GSTM1  | F-5′-GAACCTCCCTGAAAAAGCTAAAGC-3′ | 58 °C | 215 bp |
|        | R-5′-GGGGTGGCTGATTTACGAGTGG-3′ |           |            |
| GSTT1  | F-5′-TTCCTAAGTGCGCTCAGATCTC-3′ | 480 bp |            |
|        | R-5′-TCAAGGGATCATGGCGAGCA-3′ |           |            |
| CYP1A1 | F-5′-GAACCTCCTGACGGCCGATCT-3′ | 312 bp |            |
|        | R-5′-GGGCTTTGGGTTGAAAAAAGCTAAAGC-3′ | | |

**Gel Electrophoresis**

The PCR products were separated by agarose electrophoresis through a 2% agarose and then visualized on the UV™ Mini Transilluminator (Bio-Rad Laboratories, Inc., Hercules, California, United States). The amplification of GSTM1 and GSTT1 primers yielded 215 bp and 480 bp PCR products, respectively, along with a 312 bp product for CYP1A1, which acted as an internal control for DNA integrity. The amplification of GSTT1/M1 genotypes is classified as either positive (when at least one GSTM1/T1 copy of the gene was present) or null. The homozygous and heterozygous characteristics for GSTT1 are represented as GSTT1 +/0 and GSTT1 +/+ , respectively, and that for GSTM1 are represented as GSTM1 +/0 and GSTM1 +/+ , respectively.

**miR-423 (rs6505162C>A) Genotyping**

T-ARMS-PCR (amplification-refractory mutation system PCR) was utilized for the detection of miR-423 genotyping (rs6505162C>A). The primers were used as previously described and depicted in Table 3.
Genomic DNA of the patient (50 ng) was amplified in a 24 μL ARMS PCR mixture containing 20 pmol of each of the mentioned primers and 12 μL from DreamTaq Green PCR Master Mix (2x) (Cat. No. K1081) (Thermo Fisher Scientific, Waltham, Massachusetts, United States). A final volume of 24ul was adjusted by adding ddH2O. Finally, 2 μL of the patient’s DNA was added. The PCR conditions were 95°C for eight minutes, followed by 38 cycles of 94°C, 60°C, and 72°C for 58, 25, and 45 seconds, respectively; and the final extension was performed at 72°C for five minutes. The gel was visualized on a gel documentation system, Gel Doc XR+ System (Bio-Rad Laboratories, Inc., Hercules, California, United States). The miR-423 PCR amplification products were separated by electrophoresis through a 2.5% agarose gel stained with ethidium bromide. The gel was visualized on the gel documentation system, Gel Doc XR+ System. Primers FI and RO amplified the C allele, which yielded a 160 bp band, whereas the same primers yielded a band of 228 bp from the T allele. Outer primers FO and RO yielded a 336 bp band, which acted as a control for DNA purity.

| ARMS primers of miR-423 genotyping (rs6505162 C>A) |
|-----------------------------------------------|
| miR-423 FO:                                  |
| 5′-TTTTCCGGATGGAGCCCGAAGTTTGA-3′             |
| 336 bp                                       |
| 62°C                                         |
| miR-423 RO:                                  |
| 5′-TTTTGCGGCAAGCTAAGCCGCAATTTCC-3′          |
| miR-423 FI (T allele):                       |
| 5′-TGAGGCGGCTCTGCTGCTGCCAA-3′               |
| 228 bp                                       |
| miR-423 RI (C allele)                        |
| 5′-CAACGCGGGAGAAGCTCAAGCGCGAGG-3′           |
| 160 bp                                       |

**TABLE 3: ARMS primers of miR-423 genotyping (rs6505162 C>A)**

ARMS: amplification-refractory mutation system

**Results**

ACE2-rs4646994 I/D

In the screening for ACE2-rs4646994 I/D gene polymorphism, DD genotype was found (Figure 3).

**FIGURE 3: Mutation-specific PCR (MS-PCR) for the detection of insertion–deletion of ACE2-rs4646994 genotyping in controls and COVID-19 case report**

M: 100 bp DNA ladder

DD genotype: C1, C2, P1a, C3, P1b, C5, C6

II genotype: C4

DI genotype: C7, C8

COVID-19: coronavirus disease 2019; PCR: polymerase chain reaction; ACE2: angiotensin-converting enzyme 2

**GST M1 and T1 Genotyping**
In the screening for GST M1 and T1 gene polymorphism, the GSTT1 genotype and a null genotype for GSTM1 were found (Figure 4).

**FIGURE 4: Multiplex PCR for the detection of glutathione S-transferase M1 and T1 genotyping controls and COVID-19 case report**

M: 100 bp DNA ladder

GSTM1/T1: C1, C2, C4, C5, C6, C7, C8

GSTM1: C4

GSTT1: P1a, P1b

COVID-19: coronavirus disease 2019; PCR: polymerase chain reaction

**miR-423 (rs6505162 C>A) Genotyping**

In the screening for miR-423 rs6505162 C>A gene polymorphism, CA genotype was found (Figure 5).

**FIGURE 5: Amplification-refractory mutation system PCR (ARMS PCR) for the detection of miR-423 (rs6505162C>A) genotyping in controls and COVID-19 case report**

M: 100 bp DNA ladder

miR-423-homozygous (CC): C5, C6

miR-423-homozygous (AA): C2, C4 & C7

miR-423-heterozygous (C/A): C1, P1a, C3, P1b & C8

**Discussion**

Severe COVID-19 in adults is characterized by dyspnea (>30 cycles/minute), low blood oxygen saturation (<93%), low ratio of partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) (<300), and/or high lung infiltrates (>50%) within 24–48 hours [8]. Similar to our case, severe illness usually begins one
Distinct miRNA profiles were also observed in patients with COVID-19 requiring oxygenation. SARS-CoV-2 preventing and treating acute COVID-19 infections mechanisms between viruses and hosts. In turn, this could help to understand therapeutic strategies for responses and characterizing the mature miRNA's target genes could help understand the molecular respiratory infections. Thus, elucidating the mechanisms of the mature miRNAs in the immunological mature miRNA's expression in the epithelial cell can lead to the pathogenesis of chronic and acute correlation with the ectopic expression of mature miRNAs. It has been reported that any deregulation of the respiratory infections, including respiratory syncytial virus and influenza virus, and there is a significant types of disorders controlling the immune system function and are associated with the pathogenesis and etiology of many molecules, and their main function is downregulating gene expression in a variety of manners, including nucleotides in length. MiRNAs are partially complementary to one or more messenger RNA (mRNA) Mature miRNAs are a class of naturally occurring, small, non-coding RNA molecules, about 21-25 nucleotides in length. MiRNAs are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is downregulating gene expression in a variety of manners, including translational repression, mRNA cleavage, and deadenylation. Mature microRNAs play an essential role in controlling the immune system function and are associated with the pathogenesis and etiology of many types of disorders [5,16]. Mature miRNAs are involved in the immunological responses to microbial and viral respiratory infections, including respiratory syncytial virus and influenza virus, and there is a significant correlation with the ectopic expression of mature miRNAs. It has been reported that any deregulation of the mature miRNA's expression in the epithelial cell can lead to the pathogenesis of chronic and acute respiratory infections. Thus, elucidating the mechanisms of the mature miRNAs in the immunological responses and characterizing the mature miRNA's target genes could help understand the molecular mechanisms between viruses and hosts. In turn, this could help to understand therapeutic strategies for preventing and treating acute COVID-19 infections [17-19].

Distinct miRNA profiles were also observed in patients with COVID-19 requiring oxygenation. SARS-CoV-2
infection induces a robust host miRNA response that could improve COVID-19 detection and patient management [16]. Numerous disorders exhibit the abnormal expression of both mature forms of miRNA-423-5p and miR-423-3p [19,20]. Recently, diabetes, obesity, and hypertension had shown downregulation of the circulating miRNA-144a, which may be due to increased inflammation, fibrosis, and the systemic effects accompanying severe COVID-19 [20].

Conclusions

Our patient, who was young and previously healthy, developed severe bilateral COVID-19 pneumonia and carried the ACE DD genotype of ACE2, (GSTM1+/+) (GSTT1−/−) genotype of GST gene, and CA genotype (heterozygosity) of MIR423 rs6505162 gene. ACE DD genotype is strongly associated with increased disease severity of COVID-19 and is also linked with high COVID-19 mortality. GSTM1 (GSTM1+/+) (GSTT1−/−) null genotype is significantly associated with a high risk for disease severity and poor survival rate. Therefore, our case report with genetic studies might encourage researchers to conduct further studies to identify populations susceptible to severe COVID-19 for targeted interventions, even in seemingly healthy individuals.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Verma S, Abbas M, Verma S, et al.: Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Infect Genet Evol. 2021; 91:104801. 10.1016/j.meegid.2021.104801
2. Saadat M: An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19. Clin Chim Acta. 2020, 508:213-6. 10.1016/j.cca.2020.05.041
3. Li C, Hu X, Li L, Li JH: Differential microRNA expression in the peripheral blood from human patients with COVID-19. J Clin Lab Anal. 2020, 34:e23590. 10.1002/jcla.23590
4. Jacobi A, Chung M, Bernheim A, Eber C: Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review. Clin Imaging. 2020, 64:35-42. 10.1016/j.clinimag.2020.04.001
5. Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19: Supportive Care And Antiviral Treatment Of Suspected Or Confirmed Covid-19 Infection. Saudi Ministry of Health, Riyadh, Saudi Arabia; 2021. https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf
6. Mir MM, Mir R, Alghamdi MA, Alsayed BA, Wani JI, Alharthi MH, Al-Shahrani AM: Strong association of angiotensin converting enzyme-2 gene insertion/deletion polymorphism with susceptibility to SARS-CoV-2, hypertension, coronary artery disease and COVID-19 disease mortality. J Pers Med. 2021, 11:1098. 10.3390/jpm11111098
7. Abu-Dahier F, Mir R: GETTI (rs4025935) null genotype is associated with increased risk of sickle cell disease in the populations of Tabuk-Northwestern region of Saudi Arabia. Hematology. 2017, 22:172-7. 10.1080/10245332.2016.1201631
8. Wu Z, McGoogan JM: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020, 323:1239-42. 10.1001/jama.2020.2648
9. Jain V, Yuan JM: Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020, 65:533-46. 10.1007/s00038-020-01390-7
10. Ammar A, Drapé IL, Revel MP: Lung caviation in COVID-19 pneumonia. Diagn Interv Imaging. 2021, 102:117-8. 10.1016/j.dii.2020.09.007
11. Xu Z, Pan A, Zhou H: Rare CT feature in a COVID-19 patient: caviation. Diagn Interv Radiol. 2020, 26:380-1. 10.1515/dir.2020.2018
12. Dyer O: Covid-19: black people and other minorities are hardest hit in US. BMJ. 2020, 369:m1483. 10.1136/bmj.m1483
13. Allocati N, Masulli M, Di Ilio C, Federici L: Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018, 7:8. 10.1038/s41389-017-0025-3
14. Abbas M, Verma S, Verma S, et al.: Association of GSTM1 and GSTT1 gene polymorphisms with COVID-19 susceptibility and its outcome. J Med Virol. 2021, 93:5446-51. 10.1002/jmv.27076
15. Ding Z, Wang K, Li J, Tan Q, Tan W, Guo G: Association between glutathione S-transferase gene M1 and T1 polymorphisms and chronic obstructive pulmonary disease risk: A meta-analysis. Clin Genet. 2019, 95:53-62. 10.1111/cge.13373
16. Farr RJ, Rootes CL, Rowntree LC, et al.: Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog. 2021, 17:e1009759. 10.1371/journal.ppat.1009759
17. Pinilla L, Bentiz JD, González J, Torres G, Barbé F, de Gonzalo-Calvo D: Peripheral blood microRNAs and
the COVID-19 patient: methodological considerations, technical challenges and practice points. RNA Biol. 2021, 18:688-95. 10.1080/15476286.2021.1885188

18. Wang Y, Zhu X, Jiang XM, et al.: Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients. Signal Transduct Target Ther. 2021, 6:500. 10.1038/s41992-021-00716-y

19. Jha CK, Mir R, Elfaki I, et al.: Potential impact of microRNA-423 gene variability in coronary artery disease. Endocr Metab Immune Disord Drug Targets. 2019, 19:67-74. 10.2174/1871530318666181005095724

20. Mu X, Wang H, Li H: Silencing of long noncoding RNA H19 alleviates pulmonary injury, inflammation, and fibrosis of acute respiratory distress syndrome through regulating the microRNA-423-5p/FOXA1 axis. Exp Lung Res. 2021, 47:183-97. 10.1080/01902148.2021.1887967